What's new

Human medicines European public assessment report (EPAR): Opfolda, miglustat, Date of authorisation: 26/06/2023, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Opfolda, miglustat, Date of authorisation: 26/06/2023, Revision: 3, Status: Authorised

Feb 14, 2025 - 14:10
 0
Human medicines European public assessment report (EPAR): Opfolda, miglustat, Date of authorisation: 26/06/2023, Revision: 3, Status: Authorised
Human medicines European public assessment report (EPAR): Opfolda, miglustat, Date of authorisation: 26/06/2023, Revision: 3, Status: Authorised
Read More

Tags:

Previous Article

‘Road map’ outlining how cancers spread offers hope for new treatments

Next Article

Emerging British designers look to Paris for growth as London Show Rooms returns...

Related Posts

Herbal medicinal product: Betulae folium, Betula pendula Roth,Betula pubescens Ehrh., F: Assessment finalised

Herbal medicinal product: Betulae folium, Betula pendul...

Feb 28, 2025  0

Human medicines European public assessment report (EPAR): Pluvicto, lutetium (177Lu) vipivotide tetraxetan, Date of authorisation: 09/12/2022, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 19, 2025  0

Human medicines European public assessment report (EPAR): Spexotras, trametinib, Date of authorisation: 05/01/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025  0